5 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Findings provide real-world evidence to guide clinical management of these rare malignancies and show complete resection remains the cornerstone of survival in TETs.
Cetuximab-induced skin toxicity was independently associated with improved OS in R/M HNSCC patients treated with the EXTREME regimen, suggesting its potential role as a pharmacodynamic biomarker of cetuximab efficacy.
Background: Pathological complete response (pCR) following neoadjuvant systemic therapy (NST) is associated with improved outcomes in breast cancer. We evaluated the association between PET/CT-derived metabolic parameters and pCR and explored whether these associations differed according to molecular subtype. Methods:...
In patients with HR+/HER2− metastatic breast cancer, the site of first progression after CDK4/6 inhibitor therapy may help estimate subsequent prognosis, and routinely available imaging findings may add practical value when assessing risk after CDK4/6 inhibitor failure.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
